在早期症状性阿尔茨海默氏病的多纳纳马布暴露-反应
Ivelina Gueorguieva1, Kay Chow1, Laiyi Chua2
1Department of Global Pharmacokinetics/Pharmacodymanics/Pharmacometrics, Eli Lilly and Company, Bracknell, Berkshire, UK.
概括
这项研究使用了药理动力学/药理动力学建模来分析阿尔茨海默氏症早期的多纳尼马布. 平坦剂量是有效的,显示donanemab可以减少粉样质斑块,并减缓疾病的进展.
科学领域:
- 药理动力学和药理动力学
- 神经退行性疾病 神经退行性疾病
- 临床试验分析
背景情况:
- 阿尔茨海默病 (AD) 构成了重大挑战,需要新的治疗策略.
- 了解药物暴露及其对疾病标志物的影响对于优化治疗至关重要.
研究的目的:
- 确定影响多纳尼马布暴露的因素,粉样斑块负担和早期症状性阿尔茨海默病的临床疗效.
- 为了全面分析,使用种群药理动力学/药理动力学 (PK/PD) 方法.
主要方法:
- 对多纳尼马布试验参与者的分析 (NCT02624778;NCT03367403;NCT04437511).
- 用间接响应PK/PD和疾病进展模型来描述粉样蛋白斑块降低的剂量和暴露-反应关系.
主要成果:
- 多纳内马布PK表现为双相分布,终端消除半衰期为12.1天.
- 粉样蛋白减少与血清donanemab度>15μg/mL相关.
- 模拟表明,治疗后的斑块再积累率为2.8个百分/年.
- 在iADRS和CDR-SB得分中观察到~30%的疾病进展减少.
结论:
- 人口PK/PD模型可以指导未来临床试验中的多纳马布剂量策略.
- 由于与基于体重的剂量相比,暴露指标相似,因此采用了均剂量.
- 多纳内马布暴露受体重和抗体标位的影响,尽管临床上没有显著影响.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.在CDR-SB中使用.粉样蛋白质斑块是如何形成的认知/功能终点的终点.疾病的进展 疾病的进展没有的,没有的,没有的.风险暴露 风险暴露 风险暴露对于iADRS来说,这是一个很大的问题.非线性混合效应建模非线性混合效应建模更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.9K
相关概念视频
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
01:26Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673